Whilst waiting for new news I thought I would revisit timelines for trofinetide to see what the "going it alone" strategy could mean and here are my assumptions on timelines as a conservative estimate. I have, conservatively, an FDA announcement occurring in September 2027 so 3 years from now.
What will be interesting is the period between top line results and the FDA announcement whether this would be the time a take over would occur as waiting until FDA approval to then be taken over will considerably delay the launch of the drug to the market (as we saw how well Acadia prepared for this well before the FDA announcement).
PMS Phase III Trial in NNZ-2591
Trial Commencement: 1st March 2025
Recruitment commences with 1st dose: July 2025 (5 mths)
Trial enrolment complete: December 2025 (5 mths)
Top line results announced: May 2026 (5 mths)
NDA submitted to FDA: January 2027 (8 mths)
NDA accepted by FDA: March 2027 (2 mths)
FDA approval (hopefully): September 2027 (6 mths)
Neuren Trofinetide announcements:
31/10/2019- Neuren announce that Acadia has commenced Phase 3 trial
17/03/2020- Neuren announce first patient dosed and that results are expected in 2021 & marketing approval in 2022
05/08/2021- Neuren announce completed enrolment of Lavender trial with top line results in Q4 2021
07/12/2021- Neuren announce positive top line data for trofinetide and plan NDA meeting with FDA Q1 2022 and NDA application mid 2022
19/07/2022- Neuren announce Acadia submitted NDA to FDA for trofinetide
13/09/2022- Neuren announce NDA accepted for priority review of trofinetide
13/03/2023- Neuren announce FDA approval for Daybue
18/04/2023- Neuren announce Daybue launched in US
- Forums
- ASX - By Stock
- Share Price
Whilst waiting for new news I thought I would revisit timelines...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B |
Open | High | Low | Value | Volume |
$14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $13.99 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.07 | 6644 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 13.990 |
1 | 300 | 13.970 |
1 | 1432 | 13.950 |
2 | 1230 | 13.900 |
1 | 720 | 13.890 |
Price($) | Vol. | No. |
---|---|---|
14.420 | 175 | 1 |
14.500 | 2985 | 2 |
14.800 | 2850 | 2 |
14.860 | 500 | 1 |
14.960 | 445 | 1 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |